A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors

A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors

This study evaluated tumor response to olaratumab (an anti-PDGFRα monoclonal antibody) in previously treated patients with metastatic gastrointestinal stromal tumor (GIST) with or without PDGFRα mutations (cohorts 1 and 2, respectively).

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of Oncology 2017-03, Vol.28 (3), p.541-546
Hauptverfasser: Wagner, A.J, Kindler, H, Gelderblom, H, Schöffski, Patrick, Bauer, S, Hohenberger, P, Kopp, H.-G, Lopez-Martin, J.A, Peeters, M, Reichardt, P, Qin, A, Nippgen, J, Ilaria, R.L, Rutkowski, P
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:This study evaluated tumor response to olaratumab (an anti-PDGFRα monoclonal antibody) in previously treated patients with metastatic gastrointestinal stromal tumor (GIST) with or without PDGFRα mutations (cohorts 1 and 2, respectively).
ISSN:0923-7534